The most cost-effective method for developing accurate HIV-1 incidence estimates

- Identify areas of rapidly growing new HIV infections
- Evaluate the effectiveness of HIV intervention programs
- Target your resources to areas where infection rates are rising
- Identify populations well-suited for vaccine trials
- Used by the US National Surveillance System since 2005

“The BED in combination with the appropriate estimator is the preferred approach to calculating incidence of HIV infection in the US...” - US CDC 2007
Differentiates recent from long-term HIV infections using technology developed by the US CDC

Novel branched peptide provides worldwide applicability across all HIV-1 subtypes

Sample dilution of 1:101 maximizes reproducibility and can be accomplished in one simple step

Assay principle is not based on extreme dilution (e.g. detuned assays), rather on the more relevant ratio of HIV-1 specific to total IgG

Compatible with dried blood spots, allowing for flexibility of collection and use with archived specimens

Also available from Calypte:
Aware™ BED™ EIA DBS Control Pack

Find your HIV Hot Spots!